ArticleDigital health
A feasibility study on predicting disease progression in high-grade gliomas using magnetic resonance imaging habitat radiomics based on response assessment in neuro-oncology (RANO) criteria.
Article in Digital health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Investigating progression risk insights of high-grade gliomas through habitat radiomics analysis. Methods: A cohort of 89 patients with high-grade gliomas was enrolled, with 63 patients in the train cohort and 26 patients in the test cohort. The methodology involved delineating the region of interest (ROI) within the tumor area on magnetic resonance imaging images, followed by multisequence registration. The ROI was further divided into subregions using Results: The ROI was divided into three subregions, from which 36 features were extracted and selected. The habitat model, radiomics model, clinical model, and combined model were constructed by combining the extracted features with clinical data. The habitat model showed excellent predictive performance with the C-index values of 0.879 in the train cohort and 0.781 in the test cohort. Using this model, patients were classified into high-risk and low-risk groups, resulting in significantly different median progression-free survival (mPFS) times of 7 and 31 months, respectively ( Conclusion: The habitat model demonstrated outstanding predictive performance for forecasting the progression risk of patients with high-grade gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.